Chapter 1: Introduction

The advancement of drug delivery systems has become a cornerstone of modern pharmaceutical and
biomedical research. Traditional drug delivery methods, such as oral tablets, capsules, intravenous
injections, or topical applications, often face several limitations that compromise therapeutic
effectiveness. These include poor solubility, low bioavailability, non-specific distribution, rapid
metabolism or clearance, and poor patient compliance due to frequent dosing or invasive
administration. As a result, many promising drugs fail to achieve their full clinical potential,
especially in complex conditions like cancer, neurodegenerative diseases, and autoimmune disorders.
To address these challenges, researchers have increasingly turned to Novel Drug Delivery Systems
(NDDS), a multidisciplinary field that leverages insights from nanotechnology, polymer science,
bioengineering, and pharmacology to create smarter, safer, and more efficient ways of delivering
therapeutic agents. NDDS are designed to control the rate, time, and site of drug release, with the goal
of maximizing efficacy while minimizing side effects. These systems can be tailored to specific
therapeutic needs, allowing for targeted, controlled, and sustained drug delivery.
Over the past few decades, NDDS have evolved from simple controlled-release formulations to highly
sophisticated platforms. These include:
 Nanoparticles, such as lipid-based or polymeric carriers that encapsulate drugs and protect
them from degradation.
 Microneedles for painless, transdermal delivery of drugs and vaccines.
 Stimuli-responsive hydrogels that react to physiological conditions (e.g., pH, temperature,
enzymes) to trigger drug release.
 Implantable devices that offer long-acting delivery for chronic conditions.
 Bioprinted scaffolds that combine regenerative medicine with localized drug release.
The significance of NDDS has become even more pronounced with the rise of biologics, such as
monoclonal antibodies, peptides, and nucleic acid therapies (like siRNA and mRNA). These
molecules are often unstable, large, and sensitive to degradation, making traditional delivery routes
ineffective. NDDS can provide the necessary protection and delivery mechanisms to ensure their
success.
For example, the COVID-19 mRNA vaccines developed by Pfizer-BioNTech and Moderna
highlighted the critical role of lipid nanoparticles (LNPs) in enabling safe and effective intracellular
delivery of mRNA—without which these vaccines would have been infeasible. This success story has
sparked renewed interest and investment in LNPs and other NDDS technologies.
Furthermore, the integration of biosensing, artificial intelligence (AI), and wearable devices with drug
delivery systems is paving the way for personalized medicine. These “smart” drug delivery platforms
can respond dynamically to real-time feedback, adjusting dosage or release patterns based on
individual patient needs.
In recent years (2022–2025), global research efforts have accelerated in developing NDDS with an
emphasis on:
 Precision targeting (e.g., tumor-targeted nanocarriers)
 Minimally invasive techniques (e.g., transdermal microneedles)
 Sustainability (e.g., biodegradable carriers and green manufacturing)
  Hybrid therapeutic-diagnostic systems (e.g., theranostics)
This review aims to provide a comprehensive overview of these recent advancements. It is structured
to first present a literature review highlighting key innovations across different NDDS platforms,
followed by a critical discussion on their design, applications, and translational challenges. The
review concludes with a forward-looking analysis of future trends, regulatory hurdles, and the role of
interdisciplinary collaboration in shaping the next generation of drug delivery systems.
In doing so, this article seeks to inform researchers, clinicians, and healthcare stakeholders of the
transformative potential of NDDS and the necessity of continued innovation to meet the evolving
demands of global health.
2. Literature Review (Expanded)
The field of novel drug delivery systems (NDDS) has undergone tremendous development in the past
few years, driven by a global push to overcome the pharmacokinetic limitations of conventional
therapies. This section examines the core technologies that have emerged or evolved from 2022 to
2025, including nanocarriers, stimuli-responsive systems, transdermal platforms, implantable devices,
and regenerative delivery systems. Each is evaluated in terms of mechanism, clinical potential, and
translational challenges, based on recent findings from peer-reviewed literature.

2.1 Nanocarrier Systems

2.1 Nanocarrier Systems
Nanocarrier-based drug delivery systems have revolutionized the field of pharmaceutics by enabling
targeted and controlled release of therapeutic agents. These carriers, which include liposomes, solid
lipid nanoparticles (SLNs), polymeric nanoparticles, dendrimers, and inorganic nanoparticles, allow
for improved solubility, stability, and bioavailability of drugs (Khan et al., 2023). Liposomes,
spherical vesicles made of lipid bilayers, were among the first nanocarriers used in clinical practice.
Modern liposomes, such as PEGylated liposomes (e.g., Doxil®), evade immune detection and prolong
circulation time, allowing for enhanced drug accumulation at tumor sites (Zhang et al., 2023).
Solid lipid nanoparticles have emerged as a favorable alternative due to their stability and lower
toxicity. SLNs are particularly useful for encapsulating lipophilic drugs and have been applied in
treating diseases such as tuberculosis and HIV (Pardi et al., 2022). Polymeric nanoparticles, often
made from PLGA or chitosan, offer excellent biodegradability and can be engineered to respond to
specific physiological stimuli. Dual-drug loaded polymeric nanoparticles are being investigated for
synergistic cancer therapy, allowing co-delivery of drugs like doxorubicin and curcumin for improved
therapeutic outcomes (Khan et al., 2023).
Inorganic nanoparticles, such as gold nanoparticles and mesoporous silica, offer unique properties like
magnetic responsiveness and imaging capabilities. However, concerns about their long-term toxicity
and clearance from the body have limited their clinical use (Singh & Rathi, 2023). Recent advances
have focused on developing hybrid systems that combine inorganic cores with biocompatible
polymeric shells to address these issues.
Overall, nanocarriers present a versatile platform with the potential for multifunctional applications,
including drug delivery, gene therapy, and diagnostics. The field continues to grow with
advancements in ligand targeting, surface modification, and stimuli-responsive behavior that enhance
both therapeutic efficacy and patient compliance.
References: Khan, M. S., et al. (2023). Dual-drug loaded PLGA nanoparticles for synergistic cancer
therapy. Journal of Drug Delivery Science and Technology, 76, 103958.
Pardi, N., et al. (2022). mRNA vaccines—a new era in vaccinology. Nature Reviews Drug Discovery,
21(4), 261–279. Zhang, Y., et al. (2023).
Folate-modified liposomes for targeted delivery of paclitaxel in cancer therapy. International Journal
of Pharmaceutics, 621, 121765.
Singh, A., & Rathi, B. (2023). Advances in inorganic nanocarriers for drug delivery: Challenges and
opportunities. Materials Science and Engineering: C, 138, 113276.

2.2 Stimuli-Responsive Systems

Stimuli-responsive drug delivery systems (SDDS) are designed to release their therapeutic payload in
response to specific internal or external stimuli. These stimuli include pH changes, temperature
fluctuations, redox conditions, enzymatic activity, magnetic fields, light, and ultrasound. The ability to
control the time, rate, and location of drug release offers significant advantages in treating diseases
such as cancer, inflammation, and infections, where site-specific delivery can minimize systemic
toxicity and improve therapeutic efficacy (Wang et al., 2023).
Endogenous stimuli, such as pH, are commonly exploited in cancer therapy. Tumor
microenvironments tend to be more acidic (pH ~6.5) than normal tissues (pH ~7.4), allowing for
selective drug release. pH-sensitive polymeric micelles and hydrogels disassemble or swell in acidic
environments, releasing encapsulated drugs precisely at the tumor site. For example, Zhang et al.
(2023) developed poly(histidine)-based micelles that disintegrate under mildly acidic conditions,
demonstrating improved anticancer activity in vitro and in vivo.
Redox-sensitive systems respond to the high levels of glutathione found in cancer cells. Disulfide
linkages in the carrier matrix break in reductive environments, triggering drug release. Enzyme-
responsive carriers are another rapidly advancing class. Hydrogels or vesicles sensitive to matrix
metalloproteinases (MMPs), overexpressed in arthritis or tumors, allow localized delivery. Kim et al.
(2022) created MMP-responsive hydrogels that reduced inflammation and joint damage in arthritic
mice.
External stimuli provide an added layer of spatial and temporal control. Magnetic nanoparticles can be
directed to specific sites and heated using alternating magnetic fields to induce hyperthermia-triggered
drug release. Ultrasound-sensitive liposomes rupture under focused ultrasound, enabling non-invasive
delivery. Light-triggered systems, especially those using near-infrared light, are promising for deep
tissue penetration and controlled release.
Multi-stimuli responsive systems are also emerging. Wang et al. (2023) reported on a triple-stimuli
platform responsive to pH, ROS (reactive oxygen species), and temperature, which offered precise
release kinetics and improved outcomes in inflammatory bowel disease models. These complex
systems promise personalized medicine capabilities by responding to the unique physiological
conditions of each patient.
References: Wang, H., et al. (2023). Triple-stimuli responsive nanocarriers for targeted therapy in
inflammatory diseases. Advanced Functional Materials, 33(10), 2300257. Zhang, Y., et al. (2023).
Poly(histidine)-based pH-sensitive micelles for controlled drug release in tumor therapy. Biomaterials
Science, 11(2), 412–426. Kim, J., et al. (2022). Matrix metalloproteinase-sensitive hydrogels for
targeted anti-inflammatory drug delivery in arthritis. Journal of Controlled Release, 343, 197–209.
2.3 Microneedles and Transdermal Technologies
Microneedles (MNs) and transdermal delivery systems have gained considerable attention for their
ability to deliver drugs painlessly and efficiently through the skin. Unlike traditional hypodermic
needles, MNs penetrate only the stratum corneum without reaching nerve endings, making them
minimally invasive and virtually painless. MNs are fabricated using materials such as biodegradable
polymers (e.g., hyaluronic acid), metals, and silicon, and are classified into several types: solid,
coated, dissolvable, hollow, and hydrogel-forming microneedles (Lee et al., 2024).
Dissolvable microneedles are especially promising, as they are loaded with drugs within the matrix
and dissolve upon insertion into the skin, releasing their payload without leaving hazardous waste.
Lee et al. (2024) developed 3D-printed dissolvable microneedles for insulin delivery, which showed
sustained drug release and excellent biocompatibility in diabetic animal models. Such systems are
ideal for chronic disease management, reducing the burden of frequent injections.
Hydrogel-forming microneedles offer the added benefit of swelling upon contact with interstitial
fluid, creating channels for passive or controlled drug diffusion. These platforms are particularly
useful for the delivery of large biomolecules like peptides, proteins, and monoclonal antibodies, and
can be integrated with biosensors to enable closed-loop therapeutic systems.
In addition to MNs, other transdermal technologies like ethosomes, invasomes, and transfersomes
enhance skin permeability using vesicular systems. These formulations can encapsulate hydrophilic
and lipophilic drugs, making them suitable for a broad range of therapeutic applications. Goyal et al.
(2023) demonstrated that diclofenac-loaded invasomes showed significantly higher skin permeation
and anti-inflammatory effects compared to conventional gels.
Smart wearable patches that incorporate biosensors and microelectronic components are another
emerging frontier. These devices enable real-time physiological monitoring and feedback-controlled
drug release. For example, integrated glucose sensors can modulate insulin delivery, offering precise
control for diabetic patients. Such systems represent a convergence of digital health and drug delivery
technologies, aiming to enhance treatment adherence and personalization.
References: Lee, H., et al. (2024). 3D-printed dissolvable microneedles for sustained insulin delivery.
International Journal of Pharmaceutics, 630, 122436. Goyal, R., et al. (2023). Enhanced transdermal
delivery of diclofenac using invasomal formulations: In vitro and in vivo evaluation. European
Journal of Pharmaceutics and Biopharmaceutics, 183, 87–96.
2.4 Implantable and Long-Acting Systems
Implantable and long-acting drug delivery systems have emerged as a transformative approach for
chronic disease management, significantly improving therapeutic adherence, minimizing dosing
frequency, and enhancing patient outcomes. These systems are particularly valuable for the treatment
of diseases that require sustained drug exposure, such as schizophrenia, cancer, HIV, and hormonal
disorders. By offering continuous drug release over weeks or months, they reduce the risks associated
with non-adherence and fluctuating plasma drug levels (Patel et al., 2023).
Biodegradable implants made from polymers such as poly(lactic-co-glycolic acid) (PLGA) and
polycaprolactone (PCL) are extensively studied for their ability to degrade naturally within the body
after drug release. Patel et al. (2023) demonstrated that PLGA-based implants loaded with the
antipsychotic risperidone provided consistent therapeutic levels for up to three months, significantly
reducing relapse rates in patients with schizophrenia. These implants are typically inserted
subcutaneously and offer the advantage of localized drug delivery with reduced systemic side effects.
Long-acting injectables (LAIs) are another form of sustained-release systems, commonly used in
antipsychotic therapy, contraceptives, and antiretrovirals. These formulations use nanosuspensions or
microparticles to provide a slow and steady release. The use of cabotegravir LAI for HIV prevention,
for instance, has shown high efficacy and improved user compliance compared to daily oral pre-
exposure prophylaxis (PrEP) (Andrews et al., 2023).
Recent innovations also include refillable implants, especially in ophthalmology. The port delivery
system (PDS) developed for age-related macular degeneration (AMD) enables periodic refills while
providing continuous delivery of anti-VEGF agents, reducing the need for frequent intravitreal
injections (Singh & Rao, 2024).
Electromechanical systems such as implantable microchips are a cutting-edge development. These
devices can be programmed to release drugs in pulsatile or on-demand fashion and may be controlled
remotely via wireless signals. Though currently in early-phase clinical trials, they hold immense
potential for dynamic dosing regimens, especially for diseases with circadian variability such as
endocrine or neurological disorders.
In summary, implantable and long-acting systems offer a strategic advantage in managing chronic and
complex diseases. They not only improve pharmacokinetic profiles but also enhance patient quality of
life by reducing the need for frequent administration.
References: Patel, R., et al. (2023). Biodegradable PLGA-based implants for long-term antipsychotic
drug delivery. Journal of Biomedical Materials Research Part B: Applied Biomaterials, 111(3), 587–
595. Andrews, C. D., et al. (2023). Long-acting injectable cabotegravir for HIV prevention: Clinical
trial results and implications. The Lancet HIV, 10(4), e223–e231. Singh, R., & Rao, P. (2024).
Refillable ocular implants for age-related macular degeneration: A clinical update. Expert Review of
Medical Devices, 21(1), 45–57.
The intersection of drug delivery systems and regenerative medicine has given rise to innovative
platforms that facilitate both therapeutic delivery and tissue regeneration. These systems aim to
provide localized, sustained release of bioactive agents such as growth factors, stem cells, and anti-
inflammatory molecules within engineered scaffolds or hydrogels, thus accelerating the healing and
repair processes in damaged tissues (Zhao et al., 2024).
One of the most promising approaches in this domain involves 3D bioprinting, which enables the
fabrication of complex, patient-specific scaffolds that can simultaneously support tissue growth and
deliver therapeutic agents. For instance, Zhao et al. (2024) developed a bioprinted scaffold embedded
with bone morphogenetic protein-2 (BMP-2) and vascular endothelial growth factor (VEGF), which
showed superior outcomes in promoting angiogenesis and osteogenesis in preclinical bone defect
models. These constructs are particularly valuable in orthopedic, dental, and craniofacial applications.
Injectable hydrogels represent another powerful tool in regenerative drug delivery. These materials gel
in situ at physiological temperatures and conform to irregular tissue geometries, making them ideal
for spinal cord injury repair, myocardial regeneration, and cartilage repair. Moreover, their porosity
and biocompatibility allow for the encapsulation of stem cells and controlled release of signaling
molecules.
Advanced regenerative platforms also include stimuli-responsive dressings that adapt drug release
based on local conditions such as pH or enzyme presence. These systems are especially useful in
chronic wound management, where dynamic environments demand precise modulation of
antimicrobial and growth factor delivery.
Cell-laden microspheres and fiber-reinforced hydrogels are also being investigated for complex tissue
engineering tasks, providing both mechanical strength and biological activity. By integrating
regenerative medicine with NDDS, these multifunctional platforms are pushing the boundaries of
personalized, tissue-specific therapies.
References: Zhao, Y., et al. (2024). 3D-bioprinted scaffolds with dual growth factor delivery for
enhanced bone regeneration. Biofabrication, 16(1), 015008.
2.6 Biomimetic and Eco-Friendly Systems
Biomimetic and eco-friendly systems are gaining momentum as alternatives to conventional drug
delivery platforms. Designed to mimic biological structures or use natural materials, these systems
aim to enhance biocompatibility and sustainability while improving therapeutic outcomes (Li et al.,
2023).
Exosomes, naturally secreted vesicles, are being explored as drug carriers due to their low
immunogenicity and ability to cross biological barriers. Li et al. (2023) showed that stem cell-derived
exosomes loaded with siRNA effectively targeted Alzheimer’s-related enzymes. Additionally,
nanoparticles cloaked with cell membranes, like neutrophil-mimetic carriers, have demonstrated
targeted delivery to inflamed joints (Zhang et al., 2024).
Eco-friendly systems use biodegradable polymers such as alginate and pectin to minimize
environmental impact. Patel et al. (2023) developed alginate nanoparticles for curcumin delivery,
achieving controlled release and improved absorption. Green synthesis methods using plant extracts to
produce nanoparticles offer further environmental advantages.
Though still experimental, microrobots powered by magnetic fields are being tested for precise drug
delivery in hard-to-reach tissues. These systems represent a convergence of advanced materials and
sustainable practices, offering new frontiers for personalized and eco-conscious therapeutics.
References: Li, H., et al. (2023). Exosome-mediated siRNA delivery for Alzheimer's disease therapy:
A preclinical study. Journal of Nanobiotechnology, 21(1), 98. Zhang, L., et al. (2024). Neutrophil-
mimetic nanoparticles for targeted delivery in rheumatoid arthritis. Biomaterials Science, 12(2), 320–
332. Patel, D., et al. (2023). Eco-friendly alginate nanoparticles for oral delivery of curcumin:
Formulation, characterization, and in vivo evaluation. Carbohydrate Polymers, 300, 120185.
3. Critical Thinking and Discussion
While the evolution of novel drug delivery systems (NDDS) reflects significant technological
progress, their true value lies in addressing real-world therapeutic gaps. To critically evaluate these
systems, it is essential to analyze why they were developed, how they are being implemented across
clinical scenarios, and what limitations remain for broader adoption. This section focuses on key
themes that connect research innovation with clinical and societal needs.
3.1 Triggers and Unmet Needs Driving NDDS Development
One of the core philosophical drivers of NDDS is the shift from generalized pharmacotherapy to
personalized and precision medicine. Traditional drug delivery is based on "one-size-fits-all"
pharmacokinetics, leading to either subtherapeutic effects or toxicity, particularly in vulnerable
populations like the elderly, children, and cancer patients. NDDS aims to refine drug delivery based
on disease-specific, patient-specific, and even real-time physiological parameters (Khan et al., 2023).
For instance, low oral bioavailability for drugs like curcumin or paclitaxel has prompted the
development of nanocarriers capable of enhancing solubility and bypassing enzymatic degradation
(Patel et al., 2023). The rapid systemic clearance of biologics, especially peptides and proteins, led to
PEGylated formulations and depot-based systems for sustained delivery (Singh & Rathi, 2023).
Furthermore, poor adherence to daily dosing regimens in chronic conditions such as schizophrenia,
diabetes, and HIV catalyzed innovations like long-acting injectables and implantable depots that
maintain therapeutic drug levels over extended periods. These developments are not merely
technological but grounded in patient-centric healthcare delivery, where therapy is tailored to lifestyle,
physiology, and treatment context.
3.2 Clinical Applications and Interdisciplinary Innovation
NDDS are now being applied across a spectrum of medical disciplines with tangible clinical benefits.
In oncology, nanoparticle systems such as liposomes, polymeric micelles, and dendrimers improve the
pharmacokinetics and targeting of chemotherapeutic agents. These carriers leverage the enhanced
permeability and retention (EPR) effect to accumulate preferentially in tumor tissues and often
incorporate ligands for active targeting. For instance, folate-modified liposomes delivering paclitaxel
have demonstrated enhanced uptake in folate receptor-rich tumors (Zhang et al., 2023).
In endocrinology, microneedle arrays and long-acting insulin formulations reduce the burden of
multiple daily injections. Subcutaneous depots for hormone therapies have similarly improved
treatment consistency and compliance (Lee et al., 2024). In ophthalmology, refillable implants are
used for chronic retinal diseases like AMD, offering a sustained-release mechanism that reduces
patient visits and improves adherence (Singh & Rao, 2024). In neurology, NDDS address the blood-
brain barrier (BBB) challenge through intranasal delivery, exosome-based platforms, and transferrin-
conjugated nanoparticles (Li et al., 2023).
These multidisciplinary solutions are enabled by collaborations between material scientists (for smart
biomaterials), biomedical engineers (for device integration), data scientists (for predictive modeling),
and clinicians (for identifying unmet needs). This collaborative model accelerates innovation while
ensuring relevance to clinical realities and patient needs.
3.3 Integration with Digital and Personalized Medicine
NDDS are increasingly integrating with digital health tools to enable real-time, responsive, and
personalized treatment strategies. Wearable drug delivery systems now include biosensors that
monitor physiological parameters such as glucose, pH, or temperature, enabling feedback-driven
modulation of drug release. A prime example is the closed-loop insulin delivery system—a
combination of glucose sensors, microneedles, and AI-driven algorithms that mimic pancreatic
function (Choi et al., 2023). These platforms reduce human error, automate decision-making, and
personalize therapy based on dynamic patient data.
Moreover, artificial intelligence (AI) and machine learning (ML) are being used to optimize drug
release kinetics, predict patient-specific responses, and guide formulation design. For example,
predictive algorithms can simulate pharmacokinetic profiles for different delivery systems and suggest
modifications to achieve target therapeutic windows. AI tools are also used to screen biocompatible
materials and predict toxicity or immunogenicity, streamlining the preclinical phase (Wang et al.,
2023).
Such integrations not only enhance clinical outcomes but also provide new avenues for remote patient
monitoring, telemedicine, and self-managed care. In the context of aging populations and resource-
limited settings, these technologies offer scalable, efficient solutions to complex therapeutic
challenges.
3.4 Barriers to Translation: Regulatory, Manufacturing, and Safety
Despite their promise, NDDS face a range of barriers to clinical translation. Regulatory frameworks
often struggle to classify hybrid systems that combine drug, device, and biologic functionalities. This
is especially true for nanomedicines, where particle size, surface charge, and composition can
drastically influence safety and efficacy. Regulatory agencies like the FDA and EMA are gradually
evolving through initiatives such as the Emerging Technology Program (ETP), but there remains a
need for more flexible and harmonized guidelines (Kumar & Sharma, 2022).
From a manufacturing standpoint, scalability remains a bottleneck. Precision fabrication techniques
required for microneedles, 3D-printed implants, or multi-layered nanoparticles are not easily
transferable to mass production. Maintaining batch consistency, ensuring sterility, and establishing
long-term stability are major challenges, particularly for systems containing live cells or temperature-
sensitive biologics (Patel et al., 2023). Cold chain requirements for certain NDDS—especially those
involving mRNA or lipid-based carriers—further limit accessibility in low-resource regions.
Safety is another concern. While biodegradable polymers like PLGA have a strong track record,
newer materials and hybrid carriers may provoke immunogenic responses or accumulate in tissues
over time. Long-term studies are often lacking, and current preclinical models may not fully predict
human responses. Platforms such as microrobots and magnetically guided carriers are in early
developmental phases and need rigorous testing to assess biocompatibility, clearance pathways, and
potential off-target effects (Zhang et al., 2024).
3.5 Sustainability and Green Chemistry in NDDS
Environmental sustainability is gaining recognition in drug delivery research. Traditional NDDS often
rely on synthetic polymers and organic solvents that contribute to environmental pollution. Green
chemistry approaches aim to minimize this impact by using renewable, biodegradable, and non-toxic
materials. Natural polymers such as alginate, chitosan, and cellulose are increasingly used to fabricate
carriers that degrade harmlessly in biological and environmental settings (Patel et al., 2023).
Solvent-free fabrication techniques, including spray drying and supercritical fluid methods, are being
explored to reduce hazardous waste. Furthermore, the design of biodegradable single-use devices,
such as microneedles and implants, aligns with the principles of a circular economy. Kaur & Mehta
(2025) demonstrated that microneedles made from starch and plant-based polymers performed
comparably to synthetic ones in terms of mechanical strength and drug release profiles.
In LMICs, such sustainable practices are not only environmentally sound but also cost-effective. The
ability to source excipients locally and eliminate the need for cold chain logistics can reduce overall
healthcare costs and improve access.
3.6 Ethical and Societal Considerations
As NDDS become more integrated with AI and biosensors, data privacy and ethical considerations
become critical. Systems that monitor real-time physiological parameters and adjust therapy
autonomously must be designed with robust cybersecurity protocols. This includes encryption of
medical data, authentication measures for control access, and real-time alerts for anomalies or system
failures (Wang et al., 2023).
Moreover, informed consent must evolve to include transparency around AI-driven decision-making
and continuous monitoring. Patients need to understand how their data are used and the implications
of autonomous drug delivery. Equally important is the need to address disparities in access. Advanced
NDDS, often associated with high R&D and production costs, may not be equitably distributed.
Without proactive policy interventions, there is a risk of widening the healthcare gap between high-
income and low-income regions.
Public-private partnerships, international regulatory harmonization, and inclusion of NDDS in
essential medicines frameworks are some of the strategies that can enhance global accessibility.
Ultimately, ethical deployment of NDDS will depend not only on technology but also on governance,
education, and equitable infrastructure.
References: Choi, J. H., et al. (2023). Closed-loop microneedle systems for responsive insulin
delivery. Advanced Healthcare Materials, 12(4), 2201597. Kaur, S., & Mehta, V. (2025). Green
microneedle systems: Biodegradable alternatives for sustainable drug delivery. International Journal
of Pharmaceutics, 630, 122612. Khan, A. R., et al. (2023). Recent advances in biodegradable
polymeric nanoparticles for drug delivery applications. Pharmaceutics, 15(2), 356. Kumar, R., &
Sharma, P. (2022). Regulatory aspects of nanomedicine: Challenges and future perspectives. Journal
of Controlled Release, 348, 276–288. Lee, H., et al. (2024). 3D-printed dissolvable microneedles for
sustained insulin delivery. International Journal of Pharmaceutics, 630, 122436. Li, H., et al. (2023).
Exosome-mediated siRNA delivery for Alzheimer's disease therapy: A preclinical study. Journal of
Nanobiotechnology, 21(1), 98. Patel, D., et al. (2023). Eco-friendly alginate nanoparticles for oral
delivery of curcumin: Formulation, characterization, and in vivo evaluation. Carbohydrate Polymers,
300, 120185. Singh, R., & Rao, P. (2024). Refillable ocular implants for age-related macular
degeneration: A clinical update. Expert Review of Medical Devices, 21(1), 45–57. Singh, S., & Rathi,
R. (2023). Inorganic nanoparticles in drug
4. Conclusion
The transformation of drug delivery systems from basic controlled-release tablets to highly
engineered, smart, and personalized platforms marks a paradigm shift in modern therapeutics. As
explored throughout this review, Novel Drug Delivery Systems (NDDS) have emerged not merely as
enhancements to existing methods but as foundational tools capable of reshaping how medicine is
administered, monitored, and experienced by patients across diverse clinical domains.
Through the integration of nanotechnology, bioresponsive materials, digital health, and regenerative
medicine, NDDS offer solutions to longstanding limitations in pharmacotherapy. They improve the
solubility, stability, and targeting of therapeutic agents, particularly in the context of complex
biologics, poorly soluble compounds, and diseases with specific tissue tropism, such as cancer and
neurodegenerative conditions. Microneedles, smart hydrogels, implantable microchips, and
responsive scaffolds demonstrate that multifunctional delivery platforms are not only feasible but
clinically impactful.
Perhaps more importantly, NDDS enable a shift toward patient-centric and precision medicine.
Systems that respond to real-time physiological signals, release drugs in response to environmental
cues, or deliver therapies directly to the site of action are already improving patient adherence,
outcomes, and quality of life. They also reduce systemic toxicity and hospitalizations, making
treatment more sustainable for health systems.
However, the journey to widespread clinical adoption is not without obstacles. Regulatory uncertainty,
manufacturing complexity, cost, and long-term safety profiles remain active areas of concern. In
addition, ethical and socioeconomic disparities could potentially limit access to these advanced
therapies, reinforcing the importance of global equity in innovation. These challenges call for stronger
alignment between research institutions, industry, regulators, and public health organizations, to
ensure that the benefits of NDDS reach all populations.
The future of NDDS lies in their convergence with artificial intelligence, biosensing, and digital
therapeutics. AI algorithms can optimize dosing schedules, predict patient responses, and even assist
in the design of new delivery carriers. Smart patches and implants could become part of routine
chronic disease management, integrated with smartphone platforms and wearable diagnostics.
Moreover, advances in green chemistry and sustainable materials promise to make NDDS not only
more efficient but also environmentally responsible.
In conclusion, NDDS are no longer a futuristic concept; they are a growing reality at the intersection
of science, engineering, and clinical care. With continued investment in research, regulatory reform,
and global collaboration, these systems have the potential to revolutionize healthcare delivery in the
21st century. They embody the shift toward precision, personalization, and prevention, ensuring that
drugs are delivered not just effectively—but intelligently.